CJC-1295 & Ipamorelin Blend

Description

CJC-1295 and Ipamorelin – Research Use Only

CJC-1295 and Ipamorelin are two peptides frequently studied for their ability to enhance endogenous growth hormone (GH) secretion through distinct but complementary pathways. In experimental models, combining a GHRH analog (CJC-1295) with a GHRP (growth hormone-releasing peptide) like Ipamorelin has demonstrated greater stimulation of GH release than either compound used alone. This combination is often explored in research focused on anabolic signaling, recovery, and metabolic adaptation.

Research-Based Mechanisms

1. Dual Stimulation of GH Release

• CJC-1295: Acts as a GHRH analog, binding to GHRH receptors in the anterior pituitary to initiate pulsatile GH release.
• Ipamorelin: A selective GHRP that binds to ghrelin receptors (GHS-R1a), stimulating GH release via a separate pathway.

Together, they may provide a more robust and sustained GH pulse, as demonstrated in rodent models and early-phase human studies.

2. Anabolic and Recovery Support

GH and IGF-1 play essential roles in protein synthesis, tissue repair, and muscle regeneration. Research models suggest that this peptide combination may enhance recovery from overuse or trauma.

3. Lipid Metabolism and Body Composition

GH promotes lipolysis. Secretagogue combinations have been associated with increased free fatty acid availability in models of metabolic stress, suggesting utility in energy balance research.

4. Sleep and Circadian Rhythm

Endogenous GH secretion peaks during slow-wave sleep. GH secretagogues are under investigation for their potential to optimize nocturnal GH pulses and support sleep-related recovery mechanisms.

5. Neuroendocrine and Aging Research

The GH/IGF-1 axis is central to longevity research. CJC-1295 and Ipamorelin are commonly studied in models examining neuroprotective and immune-modulatory effects in aging populations.

6. Dosing Considerations

• CJC-1295 with DAC: Extended half-life (~5–8 days), enabling weekly dosing in controlled settings.
• Ipamorelin: Shorter half-life, allowing precise GH spike timing in research protocols.

7. Tolerability in Comparative Models

In animal and early human studies, Ipamorelin has demonstrated low off-target activity—notably, minimal effects on cortisol and prolactin—making it favorable in GH-targeted studies with limited side effect profiles.

Supporting References (Scientific and Medical Journals)

• Teichman, S. L. et al. (2006). Prolonged stimulation of GH and IGF-1 by CJC-1295 in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(11), 4792–4797.
• Walker, R. F. et al. (2001). GHRPs modulate lipolysis and GH release in aged rats. Neurobiology of Aging, 22(5), 857–863.
• Ghigo, E. et al. (1994). Effects of GH-releasing peptides on GH and cortisol secretion in humans. Neuroendocrinology, 59(2), 133–138.
• Smith, R. G. (2005). Development of growth hormone secretagogues: Role of ghrelin receptors. Trends in Endocrinology & Metabolism, 16(3), 129–135.
• van den Berghe, G. et al. (2001). The role of GH in metabolism and immune modulation. Hormone Research, 56(Suppl. 1), 38–43.

Disclaimer:
CJC-1295 and Ipamorelin are intended for laboratory research use only. These peptides are not approved by the FDA for human consumption or therapeutic use. Any discussion of biological effects is based on preclinical and in vitro studies and does not imply efficacy or safety in humans. These compounds are not intended to diagnose, treat, cure, or prevent any disease.

For more information, please also view CJC-1295 & Ipamorelin.